Bone morphogenetic protein 15 (BMP15) alleles predict over-response to recombinant follicle stimulation hormone and iatrogenic ovarian hyperstimulation syndrome (OHSS)

Pharmacogenetics and Genomics

Volumn 16, Issue 7, 2006, Pages 485-495

  Morón, Francisco J ^a   De Castro, Francisco ^b   Royo, Jose L ^a   Montoro, Luis ^b   Mira, Emilia ^c   Sáez, María E ^a   Real, Luis M ^a   González, Alejandro ^d   Mañes, Santos ^c   Ruiz, Agustín ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

^b HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d Centro Avanzado de Fertilidad CAF   (Spain)

Author keywords

BMP15; Controlled ovarian stimulation (COS); Ovarian hyperstimulation syndrome (OHSS); Pharmacogenetics; Pyrosequencing

Indexed keywords

BONE MORPHOGENETIC PROTEIN 15; CHORIONIC GONADOTROPIN; DNA; GONADORELIN DERIVATIVE; RECOMBINANT FOLLITROPIN; TRIPTORELIN;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ADULT; ALLELE; ARTICLE; BMP15 GENE; COMPUTER PROGRAM; CONTROLLED OVARY STIMULATION; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; FERTILIZATION IN VITRO; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; IATROGENIC DISEASE; INFERTILITY THERAPY; INTRACYTOPLASMIC SPERM INJECTION; MAJOR CLINICAL STUDY; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; OVARY FOLLICLE; OVARY HYPERSTIMULATION; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ALLELES; FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE; HUMANS; IATROGENIC DISEASE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES;

EID: 33745285312     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/01.fpc.0000215073.44589.96     Document Type: Article

References (49)

1. Salha O, Balen AH. New concepts in superovulation strategies for assisted conception treatments. Curr Opin Obstet Gynecol 2000; 76:1185-1190.
2. Kligman I, Rosenwaks Z. Differentiating clinical profiles: predicting good responders, poor responders, and hyperresponders. Fertil Steril 2001; 76:1185-1190.
3. de Castro F, Moron FJ, Montoro L, Real LM, Ruiz A. Pharmacogenetics of controlled ovarian hyperstimulation. Pharmacogenomics 2005; 6:629-637.
4. Delvigne A, Rozenberg S. Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS). Hum Reprod 2003; 9:77-96.
5. Navot D, Relou A, Birkenfeld A, Rabinowitz R, Brzezinski A, Margalioth EJ. Risk factors and prognostic variables in the ovarian hyperstimulation syndrome. Am J Obstet Gynecol 1988; 159:210-215.
6. Navot D, Margalioth EJ, Laufer N, Birkenfeld A, Relou A, Rosier A, Schenker JG. Direct correlation between plasma renin activity and severity of the ovarian hyperstimulation syndrome. Fertil Steril 1987; 48:57-61.
7. Morris RS, Paulson RJ. Increased angiotensin-converting enzyme activity in a patient with severe ovarian hyperstimulation syndrome. Fertil Steril 1999; 71:562-563.
8. Levin ER, Rosen GF, Cassidenti DL, Yee B, Meldrum D, Wisot A, Pedram A. Role of vascular endothelial cell growth factor in ovarian hyperstimulation syndrome. J Clin Invest 1998; 102:1978-1985.
9. Chen CD, Chen HF, Lu HF, Chen SU, Ho HN, Yang YS. Value of serum and follicular fluid cytokine profile in the prediction of moderate to severe ovarian hyperstimulation syndrome. Hum Reprod 2000; 15:1037-1042.
10. Barak V, Elchalal U, Edelstein M, Kalickman I, Lewin A, Abramov Y. Interleukin-18 levels correlate with severe ovarian hyperstimulation syndrome. Fertil Steril 2004; 82:415-420.
11. Enskog A, Nilsson L, Brannstrom M. Peripheral blood concentrations of inhibin B are elevated during gonadotrophin stimulation in patients who later develop ovarian OHSS and inhibin A concentrations are elevated after OHSS onset. Hum Reprod 2000; 15:532-538.
12. Daniel Y, Geva E, Amit A, Eshed-Englender T, Bar-Am A, Lessing JB. Soluble endothelial and platelet selectins in serum and ascitic fluid of women with ovarian hyperstimulation syndrome. Am J Reprod Immunol 2001; 45:154-160.
13. Mozes M, Bogokowsky H, Antebi E, Lunenfeld B, Rabau E, Serr DM, et al. Thromboembolic phenomena after ovarian stimulation with human gonadotrophins. Lancet 1965; 2:1213-1215.
14. Cluroe AD, Synek BJ. A fatal case of ovarian hyperstimulation syndrome with cerebral infarction. Pathology 1995; 27:344-346.
15. Beerendonk CC, van Dop PA, Braat DD, Merkus JM. Ovarian hyperstimulation syndrome: facts and fallacies. Obstet Gynecol Surv 1998; 53:439-449.
16. Semba S, Moriya T, Youssef EM, Sasano H. An autopsy case of ovarian hyperstimulation syndrome with massive pulmonary edema and pleural effusion. Pathol Int 2000; 50:549-552.
17. Georgiou I, Konstantelli M, Syrrou M, Messinis IE, Lolis DE. Oestrogen receptor gene polymorphisms and ovarian stimulation for in-vitro fertilization. Hum Reprod 1997; 12:1430-1433.
18. Sundarrajan C, Liao WX, Roy AC, Ng SC. Association between estrogen receptor-beta gene polymorphisms and ovulatory dysfunctions in patients with menstrual disorders. J Clin Endocrinol Metab 2001; 86:135-139.
19. Perez Mayorga M, Gromoll J, Behre HM, Gassner C, Nieschlag E, Simoni M. Ovarian response to follicle-stimulating hormone (FSH) stimulation depends on the FSH receptor genotype. J Clin Endocrinol Metab 2000; 85:3365-3369.
20. Sudo S, Kudo M, Wada S, Sato O, Hsueh AJ, Fujimoto S. Genetic and functional analyses of polymorphisms in the human FSH receptor gene. Mol Hum Reprod 2002; 8:893-899.
21. de Castro F, Ruiz R, Montoro L, Perez-Hernandez D, Sanchez-Casas Padilla E, Real LM, Ruiz A. Role of follicle-stimulating hormone receptor Ser680Asn polymorphism in the efficacy of follicle-stimulating hormone. Fertil Steril 2003; 80:571-576.
22. de Castro F, Moron FJ, Montoro L, Galan JJ, Hernandez DP, Padilla ES, et al. Human controlled ovarian hyperstimulation outcome is a polygenic trait. Pharmacogenetics 2004; 14:285-293.
23. Daelemans C, Smits G, de Maertelaer V, Costagliola S, Englert Y, Vassart G, Delbaere A. Prediction of severity of symptoms in iatrogenic ovarian hyperstimulation syndrome by follicle-stimulating hormone receptor Ser680Asn polymorphism. Clin Endocrinol Metab 2004; 89:6310-6315.
24. Smits G, Olatunbosun O, Delbaere A, Pierson R, Vassart G, Costagliola S. Ovarian hyperstimulation syndrome due to a mutation in the follicle-stimulating hormone receptor. N Engl J Med 2003; 349:760-766.
25. Vasseur C, Rodien P, Beau I, Desroches A, Gerard C, de Poncheville L, et al. A chorionic gonadotropin-sensitive mutation in the follicle-stimulating hormone receptor as a cause of familial gestational spontaneous ovarian hyperstimulation syndrome. N Engl J Med 2003; 349:753-759.
26. Montanelli L, Delbaere A, Di Carlo C, Nappi C, Smits G, Vassart G, Costagliola S. A mutation in the follicle-stimulating hormone receptor as a cause of familial spontaneous ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 2004; 89:1255-1258.
27. Galloway SM, McNatty KP, Cambridge LM, Laitinen MP, Juengel JL, Jokiranta TS, et al. Mutations in an oocyte-derived growth factor gene (BMP15) cause increased ovulation rate and infertility in a dosage-sensitive manner. Nat Genet 2000; 25:279-283.
28. Chang H, Brown CW, Matzuk MM. Genetic analysis of the mammalian transforming growth factor-beta superfamily. Endocr Rev 2002; 23:787-823.
29. Wikland M, Borg J, Hamberger L, Svalander P. Simplification of IVF: minimal monitoring and the use of subcutaneous highly purified FSH administration for ovulation induction. Hum Reprod 1994; 9:1430-1436.
30. Lopata A, Johnston IW, Hoult IJ, Speirs AI. Pregnancy following intrauterine implantation of an embryo obtained by in vitro fertilization of a preovulatory egg. Fertil Steril 1980; 33:117-120.
31. Edwards RG, Steptoe PC, Purdy JM. Establishing full-term human pregnancies using cleaving embryos grown in vitro. Br J Obstet Gynaecol 1980; 87:737-756.
32. Ronaghi M, Karamohamed S, Pettersson B, Uhlen M, Nyren P. Real-time DNA sequencing using detection of pyrophosphate release. Anal Biochem 1996; 242:84-89.
33. Sasieni PD. From genotypes to genes: doubling the sample size. Biometrics 1997; 53:1253-1261.
34. Tregouet DA, Escolano S, Tiret L, Mallet A, Golmard JL. A new algorithm for haplotype-based association analysis: the Stochastic-EM algorithm. Ann Hum Genet 2004; 68:165-177.
35. Lewontin RC, Kojima K. The evolutionary dynamics of complex polymorphisms. Evolution 1960; 14:450-472.
36. Falany JL, Falany CN. Regulation of oestrogen activity by sulfation in human MCF-7 breast cancer cells. Oncol Res 1997; 9:589-596.
37. Ortmann O, Sturm R, Knuppen R, Emons G. Weak estrogenic activity of phenol red in the pituitary gonadotroph: re-evaluation of estrogen and antiestrogen effects. J Steroid Biochem 1990; 35:17-22.
38. Ben-Josef E, Yang SY, Ji TH, Bidart JM, Garde SV, Chopra DP, et al. Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR). J Urol 1999; 161:970-976.
39. Otsuka F, Shimasaki S. A negative feedback system between oocyte bone morphogenetic protein 15 and granulosa cell kit ligand: its role in regulating granulosa cell mitosis. Proc Natl Acad Sci USA 2002; 99:8060-8065.
40. Ramenghi U, Ruggieri L, Dianzani I, Rosso C, Brizzi MF, Camaschella C, et al. Human peripheral blood granulocytes and myeloid leukemic cell lines express both transcripts encoding for stem cell factor. Stem Cells 1994; 12:521-526.
41. Bodin L, Lecerf F, Pisselet C, SanCristobal M, Bibe B, Mulsant P. How many mutations are associated with increased ovulation rate and litter size and progeny of Lacaune meat sheep? Workshop on Major Genes and QTL in Sheep and Goat, Toulouse, France, 8-11 December 2003.
42. Hanrahan JP, Gregan SM, Mulsant P, Mullen M, Davis GH, Powell R, Galloway SM. Mutations in the genes for oocyte-derived growth factors GDF9 and BMP15 are associated with both increased ovulation rate and sterility in Cambridge and Belclare sheep (Ovis aries). Biol Reprod 2004; 70:900-909.
43. Yan C, Wang P, DeMayo J, DeMayo FJ, Elvin JA, Carino C, et al. Synergistic roles of bone morphogenetic protein 15 and growth differentiation factor 9 in ovarian function. Mol Endocrinol 2001; 15:854-866.
44. Di Pasquale E, Beck-Peccoz P, Persani L. Hypergonadotropic ovarian failure associated with an inherited mutation of human bone morphogenetic protein-15 (BMP15) gene. Am J Hum Genet 2004; 75:106-111.
45. Otsuka F, Yao Z, Lee T, Yamamoto S, Erickson GF, Shimasaki S. Bone morphogenetic protein-15. Identification of target cells and biological functions. J Biol Chem 2000; 275:39523-39528.
46. Otsuka F, Yamamoto S, Erickson GF, Shimasaki S. Bone morphogenetic protein-15 inhibits follicle-stimulating hormone (FSH) action by suppressing FSH receptor expression. J Biol Chem 2001; 276:11387-11392.
47. Adashi EY, Resnick CE, Hurwitz A, Ricciarelli E, Hernandez ER, Roberts CT, et al. Insulin-like growth factors: the ovarian connection. Hum Reprod 1991; 6:1213-1219.
48. Miro F, Hillier SG. Modulation of granulosa cell deoxyribonucleic acid synthesis and differentiation by activin. Endocrinology 1996; 137:464-468.
49. Thomas FH, Ethier JF, Shimasaki S, Vanderhyden BC. Follicle-stimulating hormone regulates oocyte growth by modulation of expression of oocyte and granulosa cell factors. Endocrinology 2005; 146:941-949.